Category: Pharma
Biotech Companies’ Q3 Updates: Promising Cancer Treatments on the Horizon
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER / USA News Group / News Commentary – As many biotech companies within the oncology space begin to roll out their end-of-quarter results, the...
Read MoreBreast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – With every October, breast cancer awareness surges thanks to very effective campaigns and new developments...
Read MoreFDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Oct. 4, 2024 /PRNewswire/ — USA News Group News Commentary – While some forms of cancer are seeing death rates fall, the world is...
Read MoreBIOVAXYS ANNOUNCES UPSIZING OF PRIVATE PLACEMENT
// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, Sept. 20, 2024 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or the...
Read MoreOncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study
Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study Together, these two studies support the compelling potential of pelareorep-based combination therapy to benefit...
Read MoreOncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September
SAN DIEGO and CALGARY, AB, Sept. 6, 2024 — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Chief Financial Officer Kirk...
Read MoreOncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity’s 44th Annual Growth Conference
SAN DIEGO and CALGARY, AB, Aug. 2, 2024 — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Chief Medical Officer...
Read MoreOncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights
Received productive feedback from Type C meeting with the FDA for the planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer On track to report overall survival results from randomized...
Read MorePancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates
USA News Group CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 23, 2024 — USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of...
Read MoreEarly Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment
USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 17, 2024 — USA News Group – A new study is bringing hope in the fight against one of the deadliest cancers, revealing a blood test...
Read MoreBiotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection
USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 15, 2024 — USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently...
Read MoreBiotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb
USA News Group CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 9, 2024 — In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted...
Read More